CN105637367A - 胰腺癌相关材料和方法 - Google Patents
胰腺癌相关材料和方法 Download PDFInfo
- Publication number
- CN105637367A CN105637367A CN201480056359.9A CN201480056359A CN105637367A CN 105637367 A CN105637367 A CN 105637367A CN 201480056359 A CN201480056359 A CN 201480056359A CN 105637367 A CN105637367 A CN 105637367A
- Authority
- CN
- China
- Prior art keywords
- tumor
- protein
- pancreatic
- proteins
- phosphorylation
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010061902 Pancreatic neoplasm Diseases 0.000 title claims abstract description 196
- 201000002528 pancreatic cancer Diseases 0.000 title claims abstract description 195
- 238000000034 method Methods 0.000 title claims abstract description 151
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 title claims abstract description 63
- 208000008443 pancreatic carcinoma Diseases 0.000 title claims abstract description 63
- 239000000463 material Substances 0.000 title abstract description 7
- 206010028980 Neoplasm Diseases 0.000 claims abstract description 302
- 230000014509 gene expression Effects 0.000 claims abstract description 84
- 239000003814 drug Substances 0.000 claims abstract description 60
- 230000009822 protein phosphorylation Effects 0.000 claims abstract description 31
- 238000011282 treatment Methods 0.000 claims abstract description 23
- 230000000694 effects Effects 0.000 claims abstract description 22
- 108090000623 proteins and genes Proteins 0.000 claims description 343
- 102000004169 proteins and genes Human genes 0.000 claims description 336
- 238000006366 phosphorylation reaction Methods 0.000 claims description 143
- 230000026731 phosphorylation Effects 0.000 claims description 142
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 128
- 108010001441 Phosphopeptides Proteins 0.000 claims description 104
- 239000000523 sample Substances 0.000 claims description 94
- 210000001519 tissue Anatomy 0.000 claims description 81
- 102000004196 processed proteins & peptides Human genes 0.000 claims description 80
- 229940079593 drug Drugs 0.000 claims description 57
- 102100024193 Mitogen-activated protein kinase 1 Human genes 0.000 claims description 50
- 239000000090 biomarker Substances 0.000 claims description 32
- 230000035945 sensitivity Effects 0.000 claims description 32
- 108700015928 Mitogen-activated protein kinase 13 Proteins 0.000 claims description 31
- 102100033810 RAC-alpha serine/threonine-protein kinase Human genes 0.000 claims description 31
- 102100032822 Homeodomain-interacting protein kinase 1 Human genes 0.000 claims description 28
- 101710110794 Homeodomain-interacting protein kinase 1 Proteins 0.000 claims description 28
- 102100035044 Myosin light chain kinase, smooth muscle Human genes 0.000 claims description 28
- 230000000306 recurrent effect Effects 0.000 claims description 27
- 239000003550 marker Substances 0.000 claims description 24
- 108010040082 Junctional Adhesion Molecule A Proteins 0.000 claims description 21
- 102100022304 Junctional adhesion molecule A Human genes 0.000 claims description 21
- 238000003860 storage Methods 0.000 claims description 21
- 101710198035 Myosin light chain kinase, smooth muscle Proteins 0.000 claims description 18
- 206010061289 metastatic neoplasm Diseases 0.000 claims description 17
- 230000001613 neoplastic effect Effects 0.000 claims description 17
- 101000779418 Homo sapiens RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims description 16
- 239000012472 biological sample Substances 0.000 claims description 15
- 102100028003 Catenin alpha-1 Human genes 0.000 claims description 13
- 101710106615 Catenin alpha-1 Proteins 0.000 claims description 13
- 101710113459 RAC-alpha serine/threonine-protein kinase Proteins 0.000 claims description 13
- 102100035221 Tyrosine-protein kinase Fyn Human genes 0.000 claims description 13
- 238000001294 liquid chromatography-tandem mass spectrometry Methods 0.000 claims description 13
- 230000001394 metastastic effect Effects 0.000 claims description 13
- 230000003827 upregulation Effects 0.000 claims description 13
- 102100022975 Glycogen synthase kinase-3 alpha Human genes 0.000 claims description 12
- 102000012334 Integrin beta4 Human genes 0.000 claims description 12
- 108010022238 Integrin beta4 Proteins 0.000 claims description 12
- 239000002067 L01XE06 - Dasatinib Substances 0.000 claims description 12
- 108091000080 Phosphotransferase Proteins 0.000 claims description 12
- 108010049611 glycogen synthase kinase 3 alpha Proteins 0.000 claims description 12
- 238000004949 mass spectrometry Methods 0.000 claims description 12
- 210000004923 pancreatic tissue Anatomy 0.000 claims description 12
- 102000020233 phosphotransferase Human genes 0.000 claims description 12
- 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 claims description 11
- 230000008859 change Effects 0.000 claims description 11
- ZBNZXTGUTAYRHI-UHFFFAOYSA-N Dasatinib Chemical compound C=1C(N2CCN(CCO)CC2)=NC(C)=NC=1NC(S1)=NC=C1C(=O)NC1=C(C)C=CC=C1Cl ZBNZXTGUTAYRHI-UHFFFAOYSA-N 0.000 claims description 10
- 102100023266 Dual specificity mitogen-activated protein kinase kinase 2 Human genes 0.000 claims description 10
- 101001052493 Homo sapiens Mitogen-activated protein kinase 1 Proteins 0.000 claims description 10
- 101710102899 Tyrosine-protein kinase Fyn Proteins 0.000 claims description 10
- 229960002448 dasatinib Drugs 0.000 claims description 10
- 238000012360 testing method Methods 0.000 claims description 10
- 102000043136 MAP kinase family Human genes 0.000 claims description 9
- 108091054455 MAP kinase family Proteins 0.000 claims description 9
- 102000001253 Protein Kinase Human genes 0.000 claims description 9
- 108010029869 Proto-Oncogene Proteins c-raf Proteins 0.000 claims description 9
- 238000004891 communication Methods 0.000 claims description 9
- 230000003828 downregulation Effects 0.000 claims description 9
- 238000003364 immunohistochemistry Methods 0.000 claims description 9
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 claims description 9
- 210000000496 pancreas Anatomy 0.000 claims description 9
- 108060006633 protein kinase Proteins 0.000 claims description 9
- 230000009870 specific binding Effects 0.000 claims description 9
- 101000876610 Dictyostelium discoideum Extracellular signal-regulated kinase 2 Proteins 0.000 claims description 8
- 108010023981 Histone Deacetylase 2 Proteins 0.000 claims description 8
- 102100039999 Histone deacetylase 2 Human genes 0.000 claims description 8
- 102000019149 MAP kinase activity proteins Human genes 0.000 claims description 8
- 108040008097 MAP kinase activity proteins Proteins 0.000 claims description 8
- 206010027476 Metastases Diseases 0.000 claims description 8
- 108010008707 Mucin-1 Proteins 0.000 claims description 8
- 102100025352 Serine/threonine-protein kinase MRCK alpha Human genes 0.000 claims description 8
- 101710112530 Serine/threonine-protein kinase MRCK alpha Proteins 0.000 claims description 8
- 230000027455 binding Effects 0.000 claims description 8
- 238000006243 chemical reaction Methods 0.000 claims description 8
- 210000004881 tumor cell Anatomy 0.000 claims description 8
- 108010024124 Histone Deacetylase 1 Proteins 0.000 claims description 7
- 238000001514 detection method Methods 0.000 claims description 7
- 230000009401 metastasis Effects 0.000 claims description 7
- 238000011002 quantification Methods 0.000 claims description 7
- 238000011269 treatment regimen Methods 0.000 claims description 7
- MLDQJTXFUGDVEO-UHFFFAOYSA-N BAY-43-9006 Chemical compound C1=NC(C(=O)NC)=CC(OC=2C=CC(NC(=O)NC=3C=C(C(Cl)=CC=3)C(F)(F)F)=CC=2)=C1 MLDQJTXFUGDVEO-UHFFFAOYSA-N 0.000 claims description 6
- 239000005511 L01XE05 - Sorafenib Substances 0.000 claims description 6
- 108010065917 TOR Serine-Threonine Kinases Proteins 0.000 claims description 6
- 230000029087 digestion Effects 0.000 claims description 6
- 239000012634 fragment Substances 0.000 claims description 6
- 238000012544 monitoring process Methods 0.000 claims description 6
- 239000000243 solution Substances 0.000 claims description 6
- 229960003787 sorafenib Drugs 0.000 claims description 6
- 101710146529 Dual specificity mitogen-activated protein kinase kinase 2 Proteins 0.000 claims description 5
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 5
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 5
- 108010068353 MAP Kinase Kinase 2 Proteins 0.000 claims description 5
- 101710166115 Mitogen-activated protein kinase 2 Proteins 0.000 claims description 5
- HDAJDNHIBCDLQF-RUZDIDTESA-N SCH772984 Chemical compound O=C([C@@H]1CCN(C1)CC(=O)N1CCN(CC1)C=1C=CC(=CC=1)C=1N=CC=CN=1)NC(C=C12)=CC=C1NN=C2C1=CC=NC=C1 HDAJDNHIBCDLQF-RUZDIDTESA-N 0.000 claims description 5
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 claims description 5
- 102000004142 Trypsin Human genes 0.000 claims description 5
- 108090000631 Trypsin Proteins 0.000 claims description 5
- 229940043355 kinase inhibitor Drugs 0.000 claims description 5
- 239000003757 phosphotransferase inhibitor Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 238000001356 surgical procedure Methods 0.000 claims description 5
- 239000012588 trypsin Substances 0.000 claims description 5
- 102100024192 Mitogen-activated protein kinase 3 Human genes 0.000 claims description 4
- 230000005540 biological transmission Effects 0.000 claims description 4
- 239000000872 buffer Substances 0.000 claims description 4
- 230000007423 decrease Effects 0.000 claims description 4
- 102000006495 integrins Human genes 0.000 claims description 4
- 108010044426 integrins Proteins 0.000 claims description 4
- AXTAPYRUEKNRBA-JTQLQIEISA-N n-[(2s)-1-amino-3-(3,4-difluorophenyl)propan-2-yl]-5-chloro-4-(4-chloro-2-methylpyrazol-3-yl)furan-2-carboxamide Chemical compound CN1N=CC(Cl)=C1C1=C(Cl)OC(C(=O)N[C@H](CN)CC=2C=C(F)C(F)=CC=2)=C1 AXTAPYRUEKNRBA-JTQLQIEISA-N 0.000 claims description 4
- 208000011581 secondary neoplasm Diseases 0.000 claims description 4
- WAEXFXRVDQXREF-UHFFFAOYSA-N vorinostat Chemical compound ONC(=O)CCCCCCC(=O)NC1=CC=CC=C1 WAEXFXRVDQXREF-UHFFFAOYSA-N 0.000 claims description 4
- 229960000237 vorinostat Drugs 0.000 claims description 4
- 108091023037 Aptamer Proteins 0.000 claims description 3
- 108700027649 Mitogen-Activated Protein Kinase 3 Proteins 0.000 claims description 3
- 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 3
- 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 3
- CBPNZQVSJQDFBE-FUXHJELOSA-N Temsirolimus Chemical compound C1C[C@@H](OC(=O)C(C)(CO)CO)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 CBPNZQVSJQDFBE-FUXHJELOSA-N 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 230000009977 dual effect Effects 0.000 claims description 3
- 230000001747 exhibiting effect Effects 0.000 claims description 3
- 230000002401 inhibitory effect Effects 0.000 claims description 3
- 150000007523 nucleic acids Chemical group 0.000 claims description 3
- 238000012545 processing Methods 0.000 claims description 3
- 229960000235 temsirolimus Drugs 0.000 claims description 3
- QFJCIRLUMZQUOT-UHFFFAOYSA-N temsirolimus Natural products C1CC(O)C(OC)CC1CC(C)C1OC(=O)C2CCCCN2C(=O)C(=O)C(O)(O2)C(C)CCC2CC(OC)C(C)=CC=CC=CC(C)CC(C)C(=O)C(OC)C(O)C(C)=CC(C)C(=O)C1 QFJCIRLUMZQUOT-UHFFFAOYSA-N 0.000 claims description 3
- 230000010365 information processing Effects 0.000 claims description 2
- 102000039446 nucleic acids Human genes 0.000 claims description 2
- 108020004707 nucleic acids Proteins 0.000 claims description 2
- 239000012474 protein marker Substances 0.000 claims description 2
- 229940068117 sprycel Drugs 0.000 claims description 2
- 230000003247 decreasing effect Effects 0.000 claims 3
- 102000015616 Histone Deacetylase 1 Human genes 0.000 claims 2
- 101100087590 Homo sapiens RICTOR gene Proteins 0.000 claims 2
- 102000046941 Rapamycin-Insensitive Companion of mTOR Human genes 0.000 claims 2
- 108700019586 Rapamycin-Insensitive Companion of mTOR Proteins 0.000 claims 2
- 102000013530 TOR Serine-Threonine Kinases Human genes 0.000 claims 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 2
- 101001031598 Dictyostelium discoideum Probable serine/threonine-protein kinase fhkC Proteins 0.000 claims 1
- 101001018085 Lysobacter enzymogenes Lysyl endopeptidase Proteins 0.000 claims 1
- 102100034256 Mucin-1 Human genes 0.000 claims 1
- 230000001105 regulatory effect Effects 0.000 abstract description 39
- 230000019491 signal transduction Effects 0.000 abstract description 31
- 230000004913 activation Effects 0.000 abstract description 24
- 239000003596 drug target Substances 0.000 abstract description 17
- 235000018102 proteins Nutrition 0.000 description 226
- 102000007982 Phosphoproteins Human genes 0.000 description 38
- 108010089430 Phosphoproteins Proteins 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 32
- GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 27
- 238000004458 analytical method Methods 0.000 description 26
- 238000001597 immobilized metal affinity chromatography Methods 0.000 description 17
- 102000004190 Enzymes Human genes 0.000 description 15
- 108090000790 Enzymes Proteins 0.000 description 15
- 201000011510 cancer Diseases 0.000 description 15
- 229940088598 enzyme Drugs 0.000 description 15
- 238000003556 assay Methods 0.000 description 13
- 210000001650 focal adhesion Anatomy 0.000 description 13
- 210000001578 tight junction Anatomy 0.000 description 13
- 230000033228 biological regulation Effects 0.000 description 11
- 230000001225 therapeutic effect Effects 0.000 description 11
- 241000282414 Homo sapiens Species 0.000 description 10
- 108010074596 Myosin-Light-Chain Kinase Proteins 0.000 description 10
- 108010002321 Tight Junction Proteins Proteins 0.000 description 9
- 102000000591 Tight Junction Proteins Human genes 0.000 description 9
- 238000013459 approach Methods 0.000 description 9
- 230000012292 cell migration Effects 0.000 description 9
- 150000002500 ions Chemical class 0.000 description 9
- 238000002271 resection Methods 0.000 description 9
- -1 AEZS-131 Chemical compound 0.000 description 8
- 150000001413 amino acids Chemical class 0.000 description 8
- 230000037361 pathway Effects 0.000 description 8
- 238000002965 ELISA Methods 0.000 description 7
- 102100039996 Histone deacetylase 1 Human genes 0.000 description 7
- 102000007298 Mucin-1 Human genes 0.000 description 7
- 230000005764 inhibitory process Effects 0.000 description 7
- 230000011664 signaling Effects 0.000 description 7
- 238000001228 spectrum Methods 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 108010085238 Actins Proteins 0.000 description 6
- 102000007469 Actins Human genes 0.000 description 6
- 102000015735 Beta-catenin Human genes 0.000 description 6
- 108060000903 Beta-catenin Proteins 0.000 description 6
- 230000015572 biosynthetic process Effects 0.000 description 6
- 230000000875 corresponding effect Effects 0.000 description 6
- 230000006870 function Effects 0.000 description 6
- 238000007417 hierarchical cluster analysis Methods 0.000 description 6
- 238000002372 labelling Methods 0.000 description 6
- 102000016914 ras Proteins Human genes 0.000 description 6
- 108010007457 Extracellular Signal-Regulated MAP Kinases Proteins 0.000 description 5
- 101100193693 Kirsten murine sarcoma virus K-RAS gene Proteins 0.000 description 5
- OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 5
- 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 5
- 108091008611 Protein Kinase B Proteins 0.000 description 5
- 108010026552 Proteome Proteins 0.000 description 5
- 238000000692 Student's t-test Methods 0.000 description 5
- 239000012190 activator Substances 0.000 description 5
- 239000002246 antineoplastic agent Substances 0.000 description 5
- 229940041181 antineoplastic drug Drugs 0.000 description 5
- 238000001574 biopsy Methods 0.000 description 5
- 150000001875 compounds Chemical class 0.000 description 5
- 238000003745 diagnosis Methods 0.000 description 5
- 230000007717 exclusion Effects 0.000 description 5
- 206010073071 hepatocellular carcinoma Diseases 0.000 description 5
- 231100000844 hepatocellular carcinoma Toxicity 0.000 description 5
- 238000004128 high performance liquid chromatography Methods 0.000 description 5
- 239000003112 inhibitor Substances 0.000 description 5
- 238000004393 prognosis Methods 0.000 description 5
- 230000004083 survival effect Effects 0.000 description 5
- 238000012353 t test Methods 0.000 description 5
- OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 5
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 4
- 108050002772 E3 ubiquitin-protein ligase Mdm2 Proteins 0.000 description 4
- 102000012199 E3 ubiquitin-protein ligase Mdm2 Human genes 0.000 description 4
- 102100035118 LIM and SH3 domain protein 1 Human genes 0.000 description 4
- 101710162163 LIM and SH3 domain protein 1 Proteins 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 102100023085 Serine/threonine-protein kinase mTOR Human genes 0.000 description 4
- 210000002867 adherens junction Anatomy 0.000 description 4
- 230000031018 biological processes and functions Effects 0.000 description 4
- 238000012512 characterization method Methods 0.000 description 4
- 230000002596 correlated effect Effects 0.000 description 4
- 210000004292 cytoskeleton Anatomy 0.000 description 4
- 230000001419 dependent effect Effects 0.000 description 4
- 238000013461 design Methods 0.000 description 4
- 238000010494 dissociation reaction Methods 0.000 description 4
- 230000005593 dissociations Effects 0.000 description 4
- 230000007705 epithelial mesenchymal transition Effects 0.000 description 4
- 238000002474 experimental method Methods 0.000 description 4
- 230000012010 growth Effects 0.000 description 4
- 210000000301 hemidesmosome Anatomy 0.000 description 4
- 238000002347 injection Methods 0.000 description 4
- 239000007924 injection Substances 0.000 description 4
- 238000005259 measurement Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 230000002246 oncogenic effect Effects 0.000 description 4
- 230000002018 overexpression Effects 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 238000000513 principal component analysis Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000000575 proteomic method Methods 0.000 description 4
- 230000009467 reduction Effects 0.000 description 4
- 108091006024 signal transducing proteins Proteins 0.000 description 4
- 238000012799 strong cation exchange Methods 0.000 description 4
- 239000000758 substrate Substances 0.000 description 4
- 230000036962 time dependent Effects 0.000 description 4
- 206010006187 Breast cancer Diseases 0.000 description 3
- 208000026310 Breast neoplasm Diseases 0.000 description 3
- 108010069682 CSK Tyrosine-Protein Kinase Proteins 0.000 description 3
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 3
- 101100342473 Drosophila melanogaster Raf gene Proteins 0.000 description 3
- 102100023401 Dual specificity mitogen-activated protein kinase kinase 6 Human genes 0.000 description 3
- 101710146516 Dual specificity mitogen-activated protein kinase kinase 6 Proteins 0.000 description 3
- 238000004252 FT/ICR mass spectrometry Methods 0.000 description 3
- 102000013366 Filamin Human genes 0.000 description 3
- 108060002900 Filamin Proteins 0.000 description 3
- 102100041003 Glutamate carboxypeptidase 2 Human genes 0.000 description 3
- 108010033040 Histones Proteins 0.000 description 3
- 208000007433 Lymphatic Metastasis Diseases 0.000 description 3
- 108700012928 MAPK14 Proteins 0.000 description 3
- 102000004232 Mitogen-Activated Protein Kinase Kinases Human genes 0.000 description 3
- 108090000744 Mitogen-Activated Protein Kinase Kinases Proteins 0.000 description 3
- 241000699670 Mus sp. Species 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 108091005804 Peptidases Proteins 0.000 description 3
- 108090000315 Protein Kinase C Proteins 0.000 description 3
- 102000003923 Protein Kinase C Human genes 0.000 description 3
- 101100523543 Rattus norvegicus Raf1 gene Proteins 0.000 description 3
- 102100029437 Serine/threonine-protein kinase A-Raf Human genes 0.000 description 3
- 101710178063 Serine/threonine-protein kinase A-Raf Proteins 0.000 description 3
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 3
- 239000004473 Threonine Substances 0.000 description 3
- 102100031167 Tyrosine-protein kinase CSK Human genes 0.000 description 3
- 101100523549 Xenopus laevis raf1 gene Proteins 0.000 description 3
- 101150037250 Zhx2 gene Proteins 0.000 description 3
- 230000001594 aberrant effect Effects 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- 230000030833 cell death Effects 0.000 description 3
- 230000009087 cell motility Effects 0.000 description 3
- 230000001413 cellular effect Effects 0.000 description 3
- 238000007405 data analysis Methods 0.000 description 3
- 238000011161 development Methods 0.000 description 3
- 230000018109 developmental process Effects 0.000 description 3
- 239000000890 drug combination Substances 0.000 description 3
- 239000012636 effector Substances 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 238000000589 high-performance liquid chromatography-mass spectrometry Methods 0.000 description 3
- 230000003993 interaction Effects 0.000 description 3
- 201000010985 invasive ductal carcinoma Diseases 0.000 description 3
- 210000004185 liver Anatomy 0.000 description 3
- 239000012139 lysis buffer Substances 0.000 description 3
- 230000035800 maturation Effects 0.000 description 3
- 239000012528 membrane Substances 0.000 description 3
- 238000002493 microarray Methods 0.000 description 3
- 238000013508 migration Methods 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 230000004048 modification Effects 0.000 description 3
- 238000012986 modification Methods 0.000 description 3
- 230000035772 mutation Effects 0.000 description 3
- 231100000590 oncogenic Toxicity 0.000 description 3
- 102000027450 oncoproteins Human genes 0.000 description 3
- 108091008819 oncoproteins Proteins 0.000 description 3
- 108091005981 phosphorylated proteins Proteins 0.000 description 3
- 229920003259 poly(silylenemethylene) Polymers 0.000 description 3
- 239000000047 product Substances 0.000 description 3
- 230000035755 proliferation Effects 0.000 description 3
- 238000003127 radioimmunoassay Methods 0.000 description 3
- CCEKAJIANROZEO-UHFFFAOYSA-N sulfluramid Chemical group CCNS(=O)(=O)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)C(F)(F)F CCEKAJIANROZEO-UHFFFAOYSA-N 0.000 description 3
- 238000004885 tandem mass spectrometry Methods 0.000 description 3
- 238000002626 targeted therapy Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000001262 western blot Methods 0.000 description 3
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 2
- MLKBWFQLENQJAR-UHFFFAOYSA-N (Z)-Diversin Natural products C1=CC(=O)OC2=CC(OCCC(C)=CC(=O)C=C(C)C)=CC=C21 MLKBWFQLENQJAR-UHFFFAOYSA-N 0.000 description 2
- KKVYYGGCHJGEFJ-UHFFFAOYSA-N 1-n-(4-chlorophenyl)-6-methyl-5-n-[3-(7h-purin-6-yl)pyridin-2-yl]isoquinoline-1,5-diamine Chemical compound N=1C=CC2=C(NC=3C(=CC=CN=3)C=3C=4N=CNC=4N=CN=3)C(C)=CC=C2C=1NC1=CC=C(Cl)C=C1 KKVYYGGCHJGEFJ-UHFFFAOYSA-N 0.000 description 2
- 102000003730 Alpha-catenin Human genes 0.000 description 2
- 108090000020 Alpha-catenin Proteins 0.000 description 2
- 102100039378 Ankyrin repeat domain-containing protein 6 Human genes 0.000 description 2
- 101710122292 Ankyrin repeat domain-containing protein 6 Proteins 0.000 description 2
- 238000012935 Averaging Methods 0.000 description 2
- 102000043139 CK2 family Human genes 0.000 description 2
- 108091054872 CK2 family Proteins 0.000 description 2
- 101150068199 CSRP1 gene Proteins 0.000 description 2
- 101100181137 Caenorhabditis elegans pkc-3 gene Proteins 0.000 description 2
- 102000000584 Calmodulin Human genes 0.000 description 2
- 108010041952 Calmodulin Proteins 0.000 description 2
- 102000052052 Casein Kinase II Human genes 0.000 description 2
- 108010010919 Casein Kinase II Proteins 0.000 description 2
- 102000005403 Casein Kinases Human genes 0.000 description 2
- 108010031425 Casein Kinases Proteins 0.000 description 2
- 102100034031 Cytohesin-2 Human genes 0.000 description 2
- 102100036238 Dihydropyrimidinase Human genes 0.000 description 2
- 101100269980 Drosophila melanogaster aPKC gene Proteins 0.000 description 2
- 206010059866 Drug resistance Diseases 0.000 description 2
- 102000001267 GSK3 Human genes 0.000 description 2
- 102100030708 GTPase KRas Human genes 0.000 description 2
- 208000032612 Glial tumor Diseases 0.000 description 2
- 206010018338 Glioma Diseases 0.000 description 2
- 108090000079 Glucocorticoid Receptors Proteins 0.000 description 2
- 102100033417 Glucocorticoid receptor Human genes 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 2
- 108010051975 Glycogen Synthase Kinase 3 beta Proteins 0.000 description 2
- 102100038104 Glycogen synthase kinase-3 beta Human genes 0.000 description 2
- 102100033325 Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 Human genes 0.000 description 2
- 101150113453 Gsk3a gene Proteins 0.000 description 2
- 101000870120 Homo sapiens Cytohesin-2 Proteins 0.000 description 2
- 101000926793 Homo sapiens Golgi-specific brefeldin A-resistance guanine nucleotide exchange factor 1 Proteins 0.000 description 2
- 101001035024 Homo sapiens Histone deacetylase 1 Proteins 0.000 description 2
- 101000712969 Homo sapiens Ras association domain-containing protein 5 Proteins 0.000 description 2
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 2
- 102100027869 Moesin Human genes 0.000 description 2
- 108010006519 Molecular Chaperones Proteins 0.000 description 2
- 102000015728 Mucins Human genes 0.000 description 2
- 108010063954 Mucins Proteins 0.000 description 2
- 101100381978 Mus musculus Braf gene Proteins 0.000 description 2
- 102000003945 NF-kappa B Human genes 0.000 description 2
- 108010057466 NF-kappa B Proteins 0.000 description 2
- 108700020796 Oncogene Proteins 0.000 description 2
- 206010033128 Ovarian cancer Diseases 0.000 description 2
- 206010061535 Ovarian neoplasm Diseases 0.000 description 2
- 108700043304 PKC-3 Proteins 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- 102100035031 Palladin Human genes 0.000 description 2
- 101710128215 Palladin Proteins 0.000 description 2
- 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 2
- 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 description 2
- 102100033239 Ras association domain-containing protein 5 Human genes 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- 101710172711 Structural protein Proteins 0.000 description 2
- 229910010413 TiO 2 Inorganic materials 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- 230000002159 abnormal effect Effects 0.000 description 2
- 230000005856 abnormality Effects 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 230000003213 activating effect Effects 0.000 description 2
- 208000009956 adenocarcinoma Diseases 0.000 description 2
- 229940124650 anti-cancer therapies Drugs 0.000 description 2
- 238000011319 anticancer therapy Methods 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- 238000011088 calibration curve Methods 0.000 description 2
- 230000000747 cardiac effect Effects 0.000 description 2
- 230000024245 cell differentiation Effects 0.000 description 2
- 230000004709 cell invasion Effects 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 238000007621 cluster analysis Methods 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 230000003436 cytoskeletal effect Effects 0.000 description 2
- 238000013500 data storage Methods 0.000 description 2
- 238000006731 degradation reaction Methods 0.000 description 2
- 238000010586 diagram Methods 0.000 description 2
- 108091022884 dihydropyrimidinase Proteins 0.000 description 2
- 238000009826 distribution Methods 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 238000001914 filtration Methods 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 239000010439 graphite Substances 0.000 description 2
- 229910002804 graphite Inorganic materials 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 238000000370 laser capture micro-dissection Methods 0.000 description 2
- 230000003902 lesion Effects 0.000 description 2
- 239000007788 liquid Substances 0.000 description 2
- 230000004807 localization Effects 0.000 description 2
- 238000001819 mass spectrum Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 210000003716 mesoderm Anatomy 0.000 description 2
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 2
- 230000005012 migration Effects 0.000 description 2
- 108010071525 moesin Proteins 0.000 description 2
- 230000004899 motility Effects 0.000 description 2
- 238000002552 multiple reaction monitoring Methods 0.000 description 2
- 229910052757 nitrogen Inorganic materials 0.000 description 2
- 238000010606 normalization Methods 0.000 description 2
- 230000004650 oncogenic pathway Effects 0.000 description 2
- 238000011369 optimal treatment Methods 0.000 description 2
- 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 235000021317 phosphate Nutrition 0.000 description 2
- 230000023603 positive regulation of transcription initiation, DNA-dependent Effects 0.000 description 2
- 230000004481 post-translational protein modification Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000002243 precursor Substances 0.000 description 2
- 230000001737 promoting effect Effects 0.000 description 2
- 230000002285 radioactive effect Effects 0.000 description 2
- 102000009929 raf Kinases Human genes 0.000 description 2
- 108010077182 raf Kinases Proteins 0.000 description 2
- 239000013074 reference sample Substances 0.000 description 2
- 230000027994 regulation of Ras protein signal transduction Effects 0.000 description 2
- 238000007634 remodeling Methods 0.000 description 2
- 230000008439 repair process Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 102000034285 signal transducing proteins Human genes 0.000 description 2
- 241000894007 species Species 0.000 description 2
- 230000009897 systematic effect Effects 0.000 description 2
- 230000008685 targeting Effects 0.000 description 2
- 238000011144 upstream manufacturing Methods 0.000 description 2
- 230000025102 vascular smooth muscle contraction Effects 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 1
- XAUDJQYHKZQPEU-KVQBGUIXSA-N 5-aza-2'-deoxycytidine Chemical compound O=C1N=C(N)N=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 XAUDJQYHKZQPEU-KVQBGUIXSA-N 0.000 description 1
- 206010052747 Adenocarcinoma pancreas Diseases 0.000 description 1
- 208000024827 Alzheimer disease Diseases 0.000 description 1
- 238000009010 Bradford assay Methods 0.000 description 1
- 208000005623 Carcinogenesis Diseases 0.000 description 1
- 102100037398 Casein kinase I isoform epsilon Human genes 0.000 description 1
- 101710176553 Casein kinase I isoform epsilon Proteins 0.000 description 1
- 102000011632 Caseins Human genes 0.000 description 1
- 108010076119 Caseins Proteins 0.000 description 1
- 102100028914 Catenin beta-1 Human genes 0.000 description 1
- 101710174494 Catenin beta-1 Proteins 0.000 description 1
- 102000016362 Catenins Human genes 0.000 description 1
- 108010067316 Catenins Proteins 0.000 description 1
- 102000011068 Cdc42 Human genes 0.000 description 1
- 102000010970 Connexin Human genes 0.000 description 1
- 108050001175 Connexin Proteins 0.000 description 1
- 108010003591 Cyclic GMP-Dependent Protein Kinases Proteins 0.000 description 1
- 102000004654 Cyclic GMP-Dependent Protein Kinases Human genes 0.000 description 1
- LEVWYRKDKASIDU-QWWZWVQMSA-N D-cystine Chemical compound OC(=O)[C@H](N)CSSC[C@@H](N)C(O)=O LEVWYRKDKASIDU-QWWZWVQMSA-N 0.000 description 1
- 108050007016 Dishevelled Proteins 0.000 description 1
- 102000017944 Dishevelled Human genes 0.000 description 1
- 201000010374 Down Syndrome Diseases 0.000 description 1
- 102000007665 Extracellular Signal-Regulated MAP Kinases Human genes 0.000 description 1
- 102100037362 Fibronectin Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010091824 Focal Adhesion Kinase 1 Proteins 0.000 description 1
- 102100037813 Focal adhesion kinase 1 Human genes 0.000 description 1
- 229920002527 Glycogen Polymers 0.000 description 1
- 108010001483 Glycogen Synthase Proteins 0.000 description 1
- 102100033636 Histone H3.2 Human genes 0.000 description 1
- 102000003964 Histone deacetylase Human genes 0.000 description 1
- 108090000353 Histone deacetylase Proteins 0.000 description 1
- 101001052490 Homo sapiens Mitogen-activated protein kinase 3 Proteins 0.000 description 1
- 101001091538 Homo sapiens Pyruvate kinase PKM Proteins 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- AVXURJPOCDRRFD-UHFFFAOYSA-N Hydroxylamine Chemical compound ON AVXURJPOCDRRFD-UHFFFAOYSA-N 0.000 description 1
- 101150038847 K-RAS gene Proteins 0.000 description 1
- 206010027459 Metastases to lymph nodes Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 102000002151 Microfilament Proteins Human genes 0.000 description 1
- 108010040897 Microfilament Proteins Proteins 0.000 description 1
- 102100040243 Microtubule-associated protein tau Human genes 0.000 description 1
- 101710115937 Microtubule-associated protein tau Proteins 0.000 description 1
- 108060008487 Myosin Proteins 0.000 description 1
- 102000003505 Myosin Human genes 0.000 description 1
- 102000016349 Myosin Light Chains Human genes 0.000 description 1
- 108010067385 Myosin Light Chains Proteins 0.000 description 1
- 102100031455 NAD-dependent protein deacetylase sirtuin-1 Human genes 0.000 description 1
- 102100022913 NAD-dependent protein deacetylase sirtuin-2 Human genes 0.000 description 1
- BZQFBWGGLXLEPQ-UHFFFAOYSA-N O-phosphoryl-L-serine Natural products OC(=O)C(N)COP(O)(O)=O BZQFBWGGLXLEPQ-UHFFFAOYSA-N 0.000 description 1
- 108091008606 PDGF receptors Proteins 0.000 description 1
- 108010079855 Peptide Aptamers Proteins 0.000 description 1
- 229940122907 Phosphatase inhibitor Drugs 0.000 description 1
- 102000045595 Phosphoprotein Phosphatases Human genes 0.000 description 1
- 108700019535 Phosphoprotein Phosphatases Proteins 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
- 239000004365 Protease Substances 0.000 description 1
- 229940124158 Protease/peptidase inhibitor Drugs 0.000 description 1
- 108010039230 Protein Kinase C-delta Proteins 0.000 description 1
- 102100037340 Protein kinase C delta type Human genes 0.000 description 1
- 102100036547 Protein phosphatase 1 regulatory subunit 12A Human genes 0.000 description 1
- 101710081954 Protein phosphatase 1 regulatory subunit 12A Proteins 0.000 description 1
- 102100027384 Proto-oncogene tyrosine-protein kinase Src Human genes 0.000 description 1
- 101710122944 Proto-oncogene tyrosine-protein kinase Src Proteins 0.000 description 1
- 102000013009 Pyruvate Kinase Human genes 0.000 description 1
- 108020005115 Pyruvate Kinase Proteins 0.000 description 1
- 102100034911 Pyruvate kinase PKM Human genes 0.000 description 1
- 241000714474 Rous sarcoma virus Species 0.000 description 1
- 238000010847 SEQUEST Methods 0.000 description 1
- 229940124639 Selective inhibitor Drugs 0.000 description 1
- 108010041191 Sirtuin 1 Proteins 0.000 description 1
- 108010041216 Sirtuin 2 Proteins 0.000 description 1
- 102100033130 T-box transcription factor T Human genes 0.000 description 1
- 101710086566 T-box transcription factor T Proteins 0.000 description 1
- 102100036977 Talin-1 Human genes 0.000 description 1
- 101710142287 Talin-1 Proteins 0.000 description 1
- 102100036980 Talin-2 Human genes 0.000 description 1
- 101710142305 Talin-2 Proteins 0.000 description 1
- 102100031016 Transgelin-2 Human genes 0.000 description 1
- 108050006805 Transgelin-2 Proteins 0.000 description 1
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 1
- 102000001742 Tumor Suppressor Proteins Human genes 0.000 description 1
- 108010040002 Tumor Suppressor Proteins Proteins 0.000 description 1
- 101710086977 Tyrosine-protein kinase transforming protein Src Proteins 0.000 description 1
- 108091008605 VEGF receptors Proteins 0.000 description 1
- 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 1
- 102100023895 Zyxin Human genes 0.000 description 1
- 108010023249 Zyxin Proteins 0.000 description 1
- 230000016569 actin filament-based process Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 238000001042 affinity chromatography Methods 0.000 description 1
- 230000029936 alkylation Effects 0.000 description 1
- 238000005804 alkylation reaction Methods 0.000 description 1
- 239000012491 analyte Substances 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000006907 apoptotic process Effects 0.000 description 1
- 238000003491 array Methods 0.000 description 1
- 230000001174 ascending effect Effects 0.000 description 1
- 238000002820 assay format Methods 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 238000003766 bioinformatics method Methods 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 210000004556 brain Anatomy 0.000 description 1
- 102000028861 calmodulin binding Human genes 0.000 description 1
- 108091000084 calmodulin binding Proteins 0.000 description 1
- 230000036952 cancer formation Effects 0.000 description 1
- 230000005907 cancer growth Effects 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 229910052799 carbon Inorganic materials 0.000 description 1
- 231100000504 carcinogenesis Toxicity 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 108010051348 cdc42 GTP-Binding Protein Proteins 0.000 description 1
- 230000021164 cell adhesion Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 230000006037 cell lysis Effects 0.000 description 1
- 230000004663 cell proliferation Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 238000001360 collision-induced dissociation Methods 0.000 description 1
- 108091036078 conserved sequence Proteins 0.000 description 1
- 230000009260 cross reactivity Effects 0.000 description 1
- 208000031513 cyst Diseases 0.000 description 1
- 229960003067 cystine Drugs 0.000 description 1
- 230000001086 cytosolic effect Effects 0.000 description 1
- 230000006240 deamidation Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 239000012649 demethylating agent Substances 0.000 description 1
- 229950006137 dexfosfoserine Drugs 0.000 description 1
- 239000000104 diagnostic biomarker Substances 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 229940000406 drug candidate Drugs 0.000 description 1
- 238000012362 drug development process Methods 0.000 description 1
- 238000002651 drug therapy Methods 0.000 description 1
- 229940125436 dual inhibitor Drugs 0.000 description 1
- 230000008482 dysregulation Effects 0.000 description 1
- 238000000132 electrospray ionisation Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000001943 fluorescence-activated cell sorting Methods 0.000 description 1
- 235000019253 formic acid Nutrition 0.000 description 1
- 238000001502 gel electrophoresis Methods 0.000 description 1
- 230000030279 gene silencing Effects 0.000 description 1
- 101150017583 gluC gene Proteins 0.000 description 1
- 229940096919 glycogen Drugs 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 230000037417 hyperactivation Effects 0.000 description 1
- 238000003365 immunocytochemistry Methods 0.000 description 1
- 238000012309 immunohistochemistry technique Methods 0.000 description 1
- 238000001114 immunoprecipitation Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000011221 initial treatment Methods 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000000155 isotopic effect Effects 0.000 description 1
- 230000008466 key signal transduction pathway Effects 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 238000000670 ligand binding assay Methods 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000004811 liquid chromatography Methods 0.000 description 1
- 239000006166 lysate Substances 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 230000003211 malignant effect Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000001840 matrix-assisted laser desorption--ionisation time-of-flight mass spectrometry Methods 0.000 description 1
- 239000002609 medium Substances 0.000 description 1
- 201000001441 melanoma Diseases 0.000 description 1
- 238000001466 metabolic labeling Methods 0.000 description 1
- 230000011987 methylation Effects 0.000 description 1
- 238000007069 methylation reaction Methods 0.000 description 1
- 230000011278 mitosis Effects 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 230000004879 molecular function Effects 0.000 description 1
- 239000004570 mortar (masonry) Substances 0.000 description 1
- 210000000947 motile cell Anatomy 0.000 description 1
- 229940051875 mucins Drugs 0.000 description 1
- 229940124303 multikinase inhibitor Drugs 0.000 description 1
- 230000024353 muscle cell migration Effects 0.000 description 1
- 230000004118 muscle contraction Effects 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 108091008104 nucleic acid aptamers Proteins 0.000 description 1
- 230000005959 oncogenic signaling Effects 0.000 description 1
- 230000006712 oncogenic signaling pathway Effects 0.000 description 1
- 230000008520 organization Effects 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 201000002094 pancreatic adenocarcinoma Diseases 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 239000013610 patient sample Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 150000003013 phosphoric acid derivatives Chemical class 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- BZQFBWGGLXLEPQ-REOHCLBHSA-N phosphoserine Chemical compound OC(=O)[C@@H](N)COP(O)(O)=O BZQFBWGGLXLEPQ-REOHCLBHSA-N 0.000 description 1
- 230000030716 positive regulation of phosphorylation Effects 0.000 description 1
- 230000029279 positive regulation of transcription, DNA-dependent Effects 0.000 description 1
- 239000000092 prognostic biomarker Substances 0.000 description 1
- 230000004952 protein activity Effects 0.000 description 1
- 230000012846 protein folding Effects 0.000 description 1
- 230000004853 protein function Effects 0.000 description 1
- 230000006916 protein interaction Effects 0.000 description 1
- 230000009145 protein modification Effects 0.000 description 1
- 230000002797 proteolythic effect Effects 0.000 description 1
- 229940024999 proteolytic enzymes for treatment of wounds and ulcers Drugs 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000012207 quantitative assay Methods 0.000 description 1
- 238000001959 radiotherapy Methods 0.000 description 1
- 108010014186 ras Proteins Proteins 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000007363 regulatory process Effects 0.000 description 1
- 230000008521 reorganization Effects 0.000 description 1
- 230000004044 response Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 230000002207 retinal effect Effects 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 102200006539 rs121913529 Human genes 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 238000003118 sandwich ELISA Methods 0.000 description 1
- 125000003607 serino group Chemical group [H]N([H])[C@]([H])(C(=O)[*])C(O[H])([H])[H] 0.000 description 1
- 230000007781 signaling event Effects 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 230000003595 spectral effect Effects 0.000 description 1
- 238000012289 standard assay Methods 0.000 description 1
- 238000010561 standard procedure Methods 0.000 description 1
- 238000007619 statistical method Methods 0.000 description 1
- 238000012437 strong cation exchange chromatography Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- HWCKGOZZJDHMNC-UHFFFAOYSA-M tetraethylammonium bromide Chemical compound [Br-].CC[N+](CC)(CC)CC HWCKGOZZJDHMNC-UHFFFAOYSA-M 0.000 description 1
- 230000004797 therapeutic response Effects 0.000 description 1
- 239000004408 titanium dioxide Substances 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000010361 transduction Methods 0.000 description 1
- 230000026683 transduction Effects 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000000844 transformation Methods 0.000 description 1
- 230000001131 transforming effect Effects 0.000 description 1
- 230000005748 tumor development Effects 0.000 description 1
- 230000004614 tumor growth Effects 0.000 description 1
- 230000005751 tumor progression Effects 0.000 description 1
- 239000000225 tumor suppressor protein Substances 0.000 description 1
- 231100000588 tumorigenic Toxicity 0.000 description 1
- 230000000381 tumorigenic effect Effects 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000002700 urine Anatomy 0.000 description 1
- 229940124676 vascular endothelial growth factor receptor Drugs 0.000 description 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2/00—Peptides of undefined number of amino acids; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2440/00—Post-translational modifications [PTMs] in chemical analysis of biological material
- G01N2440/14—Post-translational modifications [PTMs] in chemical analysis of biological material phosphorylation
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2458/00—Labels used in chemical analysis of biological material
- G01N2458/15—Non-radioactive isotope labels, e.g. for detection by mass spectrometry
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2570/00—Omics, e.g. proteomics, glycomics or lipidomics; Methods of analysis focusing on the entire complement of classes of biological molecules or subsets thereof, i.e. focusing on proteomes, glycomes or lipidomes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Biochemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- Pathology (AREA)
- Cell Biology (AREA)
- Hospice & Palliative Care (AREA)
- Microbiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- General Physics & Mathematics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Other Investigation Or Analysis Of Materials By Electrical Means (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1314485.2 | 2013-08-13 | ||
| GBGB1314485.2A GB201314485D0 (en) | 2013-08-13 | 2013-08-13 | Materials and methods relating to pancreatic cancer |
| PCT/GB2014/052475 WO2015022530A2 (en) | 2013-08-13 | 2014-08-13 | Materials and methods relating to pancreatic cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN105637367A true CN105637367A (zh) | 2016-06-01 |
Family
ID=49262110
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201480056359.9A Pending CN105637367A (zh) | 2013-08-13 | 2014-08-13 | 胰腺癌相关材料和方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20160195536A1 (enExample) |
| EP (1) | EP3033624A2 (enExample) |
| JP (1) | JP2016535270A (enExample) |
| CN (1) | CN105637367A (enExample) |
| CA (1) | CA2920946A1 (enExample) |
| GB (1) | GB201314485D0 (enExample) |
| WO (1) | WO2015022530A2 (enExample) |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107923918A (zh) * | 2015-09-09 | 2018-04-17 | 私募蛋白质体公司 | 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法 |
| CN112585470A (zh) * | 2018-06-21 | 2021-03-30 | 乌得勒支大学控股有限责任公司 | 用于监测样品中激酶活性的方法 |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10617720B2 (en) * | 2016-10-20 | 2020-04-14 | Miltenyi Biotech, GmbH | Chimeric antigen receptor specific for tumor cells |
| BR112019012441A2 (pt) * | 2016-12-20 | 2020-04-14 | Treat4Life Ab | método para determinar mutações braf e proteína braf do tipo selvagem por espectrometria de massa |
| CN111066727B (zh) * | 2019-12-20 | 2021-08-27 | 中国人民解放军陆军军医大学 | 在低氧性血睾屏障通透中作用机制的小鼠模型构建方法 |
| IT202000016807A1 (it) * | 2020-07-10 | 2022-01-10 | Humanitas Mirasole Spa | Peptidi associati a tumore e loro impiego |
| WO2022154037A1 (ja) * | 2021-01-14 | 2022-07-21 | 公立大学法人福島県立医科大学 | がんの予後バイオマーカー |
Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726395A (zh) * | 2002-12-17 | 2006-01-25 | 北京诺赛基因组研究中心有限公司 | 胰腺癌的特异标记 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5270163A (en) | 1990-06-11 | 1993-12-14 | University Research Corporation | Methods for identifying nucleic acid ligands |
| KR970002255B1 (ko) | 1990-06-11 | 1997-02-26 | 넥스스타 파아마슈티컬드, 인크. | 핵산 리간드 |
| DE60239962D1 (de) | 2001-08-14 | 2011-06-16 | Harvard College | Absolute quantifizierung von proteinen und modifizierten formen davon mittels mehrstufiger massenspektrometrie |
| WO2004055519A2 (en) * | 2002-12-17 | 2004-07-01 | Sinogenomax Co. Ltd. | Specific markers for pancreatic cancer |
| US8346482B2 (en) * | 2003-08-22 | 2013-01-01 | Fernandez Dennis S | Integrated biosensor and simulation system for diagnosis and therapy |
| DE102006056784A1 (de) * | 2006-12-01 | 2008-06-05 | Meyer, Helmut E., Prof.Dr. | Biomarker für die Diagnose von Pankreaskrebs |
| GB0704764D0 (en) | 2007-03-12 | 2007-04-18 | Electrophoretics Ltd | Isobarically labelled reagents and methods of their use |
| CA2726531A1 (en) * | 2008-06-05 | 2009-12-10 | University Health Network | Compositions and methods for classifying lung cancer and prognosing lung cancer survival |
| CA2750818A1 (en) * | 2009-01-27 | 2010-08-05 | Proteogenix, Inc. | Biomarkers for detection of neonatal sepsis in biological fluid |
| WO2011088030A1 (en) * | 2010-01-15 | 2011-07-21 | Bryan William Jones | Disease diagnosis and treatment using computational molecular phenotyping |
| US20120309706A1 (en) * | 2010-02-01 | 2012-12-06 | Ab Science | Combined treatment of pancreatic cancer with gemcitabine and masitinib |
| EP2561368B1 (en) * | 2010-04-19 | 2017-08-02 | Biomarker Strategies, LLC. | Compositions and methods for prediction of drug sensitivity, resistance, and disease progression |
| CA2800023A1 (en) * | 2010-06-01 | 2011-12-08 | Metanomics Health Gmbh | Means and methods for diagnosing pancreatic cancer in a subject |
| ES2611479T3 (es) * | 2010-06-16 | 2017-05-09 | University Of Pittsburgh- Of The Commonwealth System Of Higher Education | Anticuerpos contra endoplasmina y su uso |
| CA2838736A1 (en) * | 2011-06-07 | 2012-12-13 | Caris Mpi, Inc. | Molecular profiling for cancer |
-
2013
- 2013-08-13 GB GBGB1314485.2A patent/GB201314485D0/en not_active Ceased
-
2014
- 2014-08-13 EP EP14755897.7A patent/EP3033624A2/en not_active Withdrawn
- 2014-08-13 CN CN201480056359.9A patent/CN105637367A/zh active Pending
- 2014-08-13 WO PCT/GB2014/052475 patent/WO2015022530A2/en not_active Ceased
- 2014-08-13 CA CA2920946A patent/CA2920946A1/en not_active Abandoned
- 2014-08-13 JP JP2016533958A patent/JP2016535270A/ja active Pending
- 2014-08-13 US US14/912,299 patent/US20160195536A1/en not_active Abandoned
Patent Citations (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1726395A (zh) * | 2002-12-17 | 2006-01-25 | 北京诺赛基因组研究中心有限公司 | 胰腺癌的特异标记 |
Non-Patent Citations (1)
| Title |
|---|
| DAVID BRITTON ET AL.: "Quantification of Pancreatic Cancer Proteome and Phosphorylome: Indicates Molecular Events Likely Contributing to Cancer and Activity of Drug Targets", 《PLOS ONE》 * |
Cited By (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107923918A (zh) * | 2015-09-09 | 2018-04-17 | 私募蛋白质体公司 | 用于开发个性化药物治疗计划和基于蛋白质组谱的靶向药物开发的方法 |
| CN112585470A (zh) * | 2018-06-21 | 2021-03-30 | 乌得勒支大学控股有限责任公司 | 用于监测样品中激酶活性的方法 |
Also Published As
| Publication number | Publication date |
|---|---|
| EP3033624A2 (en) | 2016-06-22 |
| WO2015022530A3 (en) | 2015-04-09 |
| WO2015022530A2 (en) | 2015-02-19 |
| JP2016535270A (ja) | 2016-11-10 |
| CA2920946A1 (en) | 2015-02-19 |
| GB201314485D0 (en) | 2013-09-25 |
| US20160195536A1 (en) | 2016-07-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Lucarelli et al. | Serum sarcosine increases the accuracy of prostate cancer detection in patients with total serum PSA less than 4.0 ng/ml | |
| Old et al. | Functional proteomics identifies targets of phosphorylation by B-Raf signaling in melanoma | |
| Schrödter et al. | Identification of the dopamine transporter SLC6A3 as a biomarker for patients with renal cell carcinoma | |
| Mikula et al. | Integrating proteomic and transcriptomic high-throughput surveys for search of new biomarkers of colon tumors | |
| Liu et al. | LC-MS-based plasma metabolomics and lipidomics analyses for differential diagnosis of bladder cancer and renal cell carcinoma | |
| CN105637367A (zh) | 胰腺癌相关材料和方法 | |
| Maes et al. | Proteomics in cancer research: Are we ready for clinical practice? | |
| Gajbhiye et al. | Urinary proteome alterations in HER2 enriched breast cancer revealed by multipronged quantitative proteomics | |
| Saraswat et al. | Comparative proteomic profiling of the serum differentiates pancreatic cancer from chronic pancreatitis | |
| US20240084394A1 (en) | Urinary metabolomic biomarkers for detecting colorectal cancer and polyps | |
| Hadisurya et al. | Quantitative proteomics and phosphoproteomics of urinary extracellular vesicles define putative diagnostic biosignatures for Parkinson’s disease | |
| Vellaichamy et al. | Proteomic interrogation of androgen action in prostate cancer cells reveals roles of aminoacyl tRNA synthetases | |
| Su et al. | Multi-omics analysis of brain metastasis outcomes following craniotomy | |
| HK1248316A1 (en) | Methods of assessing colorectal health of an individual | |
| Duangkumpha et al. | Discovery and qualification of serum protein biomarker candidates for cholangiocarcinoma diagnosis | |
| GB2551415A (en) | Protein biomarker panels for detecting colorectal cancer and advanced adenoma | |
| Pavlou et al. | Coupling proteomics and transcriptomics in the quest of subtype‐specific proteins in breast cancer | |
| Chinello et al. | The proteomic landscape of renal tumors | |
| Kwon et al. | Identification of novel prognosis and prediction markers in advanced prostate cancer tissues based on quantitative proteomics | |
| Wu et al. | Next-generation novel noninvasive cancer molecular diagnostics platforms beyond tissues | |
| Sun et al. | From clinic to mechanism: Proteomics‐based assessment of angiogenesis in adrenal pheochromocytoma | |
| US20200292548A1 (en) | Markers for the diagnosis of biochemical recurrence in prostate cancer | |
| Barco et al. | Untargeted LC-HRMS based-plasma metabolomics reveals 3-O-methyldopa as a new biomarker of poor prognosis in high-risk neuroblastoma | |
| Adeola et al. | In silico verification and parallel reaction monitoring prevalidation of potential prostate cancer biomarkers | |
| Zhang et al. | The impact of advanced proteomics in the search for markers and therapeutic targets of bladder cancer |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| CB02 | Change of applicant information |
Address after: London, England Applicant after: Electrophoretics Limited Applicant after: KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST Address before: surrey Applicant before: Electrophoretics Limited Applicant before: KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST |
|
| CB02 | Change of applicant information | ||
| RJ01 | Rejection of invention patent application after publication |
Application publication date: 20160601 |
|
| RJ01 | Rejection of invention patent application after publication |